These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21878231)

  • 1. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.
    Hiller DJ; Meschonat C; Kim R; Li BD; Chu QD
    Surgery; 2011 Sep; 150(3):459-65. PubMed ID: 21878231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC).
    Holm NT; Abreo F; Johnson LW; Li BD; Chu QD
    Breast Cancer Res Treat; 2009 Jan; 113(2):293-9. PubMed ID: 18270814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study.
    Mizell J; Smith M; Li BD; Ampil F; Chu QD
    Ann Surg Oncol; 2009 Oct; 16(10):2711-6. PubMed ID: 19593633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome.
    Chu QD; Panu L; Holm NT; Li BD; Johnson LW; Zhang S
    J Surg Res; 2010 Apr; 159(2):689-95. PubMed ID: 19500800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients.
    Parker CC; Kim RH; Li BD; Chu QD
    J Surg Oncol; 2012 Sep; 106(4):393-8. PubMed ID: 22473623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy.
    Hiller DJ; Li BD; Chu QD
    J Surg Res; 2011 Mar; 166(1):14-8. PubMed ID: 20828730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
    Davidson B; Dong HP; Holth A; Berner A; Risberg B
    Breast J; 2008; 14(5):476-82. PubMed ID: 18657145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
    Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
    Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
    Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
    J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
    Wolfort R; de Benedetti A; Nuthalapaty S; Yu H; Chu QD; Li BD
    Surgery; 2006 Aug; 140(2):161-9. PubMed ID: 16904965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer.
    Hiller DJ; Chu Q; Meschonat C; Panu L; Burton G; Li BD
    J Surg Res; 2009 Oct; 156(2):265-9. PubMed ID: 19665145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
    Holm N; Byrnes K; Johnson L; Abreo F; Sehon K; Alley J; Meschonat C; Md QC; Li BD
    Ann Surg Oncol; 2008 Nov; 15(11):3207-15. PubMed ID: 18719964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
    Foekens JA; Peters HA; Grebenchtchikov N; Look MP; Meijer-van Gelder ME; Geurts-Moespot A; van der Kwast TH; Sweep CG; Klijn JG
    Cancer Res; 2001 Jul; 61(14):5407-14. PubMed ID: 11454684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.